Related references
Note: Only part of the references are listed.Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma
Eshana E. Shah et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma
Zoe Van de Wyngaert et al.
BONE MARROW TRANSPLANTATION (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
Wilson I. Gonsalves et al.
BONE MARROW TRANSPLANTATION (2019)
Current status of autologous stem cell transplantation for multiple myeloma
Rama Al Hamed et al.
BLOOD CANCER JOURNAL (2019)
Rapid and Robust Mobilization of CD34+HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor
John F. DiPersio et al.
BLOOD (2019)
Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
Ga-Young Song et al.
BMC CANCER (2019)
Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens
Anthony Oyekunle et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell
Jonathan Hoggatt et al.
CELL (2018)
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis
Binod Dhakal et al.
JAMA ONCOLOGY (2018)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
S. Afifi et al.
BONE MARROW TRANSPLANTATION (2016)
Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity
Philip S. Rosenberg et al.
BLOOD (2015)
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
G. L. Uy et al.
BONE MARROW TRANSPLANTATION (2015)
G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis
A. Antar et al.
BONE MARROW TRANSPLANTATION (2015)
Hematopoietic progenitor cell mobilization with just-in-time plerixafor approach is a cost-effective alternative to routine plerixafor use
Lauren Veltri et al.
CYTOTHERAPY (2015)
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Peripheral Blood Stem Cell Mobilization in Multiple Myeloma Patients Treat in the Novel Therapy-Era With Plerixafor and G-CSF Has Superior Efficacy but Significantly Higher Costs Compared to Mobilization With Low-Dose Cyclophosphamide and G-CSF
Lubna Chaudhary et al.
JOURNAL OF CLINICAL APHERESIS (2013)
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure
L. J. Costa et al.
BONE MARROW TRANSPLANTATION (2012)
Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery
J. S. Ungerstedt et al.
MEDICAL ONCOLOGY (2012)
Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy
William A. Wood et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization
L. J. Costa et al.
BONE MARROW TRANSPLANTATION (2011)
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
John F. DiPersio et al.
BLOOD (2009)
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma
M. A. Gertz et al.
BONE MARROW TRANSPLANTATION (2009)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
S. Kumar et al.
LEUKEMIA (2007)
Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma
David Dingli et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Share Paper
